MedTrace Logo

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

NCT05392699 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-06-22

No results posted yet for this study

Summary

Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.

The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.

Conditions

  • Patients With Advanced Solid Tumors

Interventions

BIOLOGICAL

human single chain IL-12 mRNA-single dose

human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only

BIOLOGICAL

human single chain IL-12 mRNA-multiple dose

human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Ning Li, Doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2025-03-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05392699 on ClinicalTrials.gov